Open AccessRandomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome
Author(s) -
QiQi Zhou,
Meghan L Verne,
Jeremy Z. Fields,
John J. Lefante,
Sarpreet Basra,
Habeeb Salameh,
G. Nicholas Verne
Publication year - 2018
Publication title -
gut
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.413
H-Index - 293
eISSN - 1468-3288
pISSN - 0017-5749
DOI - 10.1136/gutjnl-2017-315136
Subject(s) - medicine , irritable bowel syndrome , placebo , gastroenterology , glutamine , lactulose , clinical endpoint , intestinal permeability , adverse effect , diarrhea , randomized controlled trial , pathology , biochemistry , chemistry , alternative medicine , amino acid
More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection.